MDT

85.6

-1.76%↓

118.07

-1.12%↓

VEEV

167.35

-0.11%↓

HQY

84.4

+0.63%↑

NEOG

9.24

-2.01%↓

MDT

85.6

-1.76%↓

118.07

-1.12%↓

VEEV

167.35

-0.11%↓

HQY

84.4

+0.63%↑

NEOG

9.24

-2.01%↓

MDT

85.6

-1.76%↓

118.07

-1.12%↓

VEEV

167.35

-0.11%↓

HQY

84.4

+0.63%↑

NEOG

9.24

-2.01%↓

MDT

85.6

-1.76%↓

118.07

-1.12%↓

VEEV

167.35

-0.11%↓

HQY

84.4

+0.63%↑

NEOG

9.24

-2.01%↓

MDT

85.6

-1.76%↓

118.07

-1.12%↓

VEEV

167.35

-0.11%↓

HQY

84.4

+0.63%↑

NEOG

9.24

-2.01%↓

Home・Elenco Azioni・Crinetics Pharmaceuticals Inc

Crinetics Pharmaceuticals Inc

Chiusa

SettoreSettore sanitario

39 -1.96

Acquista Vendi

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

38.57

Massimo

39.63

Metriche Chiave
By Trading Economics
Entrata	7.3M -123M
Vendite	3.7M 3.9M
EPS	-1.29
Margine di Profitto	-3,161.261
Dipendenti	594
EBITDA	20M -122M

Raccomandazioni
By TipRanks
Raccomandazioni	Fortemente da comprare
Previsioni per 12 mesi	+118.03% upside

Dividendi
By Dow Jones
Utili prossimi	7 mag 2026

Statistiche di mercato
By TradingEconomics
Capitalizzazione di Mercato	-441M 4B
Apertura precedente	40.96
Chiusura precedente	39

Notizie sul Sentiment di mercato

By Acuity

86%

14%

332 / 348 Classifica in Healthcare

Punteggio Tecnico

By Trading Central

Fiducia

Weak Bullish Evidence

30.39 / 33.46 Supporto e resistenza

Crinetics Pharmaceuticals Inc Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

16 apr 2026, 23:26 UTC

Azioni calde

Stocks to Watch: Netflix, Alcoa, Knight-Swift, NiSource

16 apr 2026, 20:41 UTC

I principali Market Mover

Netflix Shares Slide After 2Q Outlook Misses Wall Street's Expectations

16 apr 2026, 23:49 UTC

Discorsi di Mercato

Amplitude's Pivot to Oil-Linked Supply Deal Catches Bull's Eye -- Market Talk

16 apr 2026, 23:45 UTC

Discorsi di Mercato

Nikkei May Decline After Hitting Record High -- Market Talk

16 apr 2026, 23:33 UTC

Discorsi di Mercato

Principali Notizie su Eventi

Gold Edges Higher on Hopes for U.S.-Iran Deal -- Market Talk

16 apr 2026, 22:51 UTC

Discorsi di Mercato

Netflix Sees Signs That Podcasts May Boost Engagement -- Market Talk

16 apr 2026, 22:08 UTC

Utili

Netflix Chair Reed Hastings to Leave Board in June -- 3rd Update

16 apr 2026, 22:06 UTC

Utili

Lundin Mining: Earnings From Discontinued Ops in 1Q Expected to Be Positively Impacted by Unaudited Gain on Disposal of Eagle Mine, Totaling Approximately $4M >LUN.T

16 apr 2026, 22:06 UTC

Utili

Lundin Mining: Pre-Announces Items Impacting 1Q Results

16 apr 2026, 22:06 UTC

Utili

Lundin Mining: Items of Significant Impact in 1Q Expected to Include Unaudited Realized Losses on Derivative Contracts of Approximately $13M, Primarily Related to Gold Collar Contracts >LUN.T

16 apr 2026, 22:06 UTC

Utili

Lundin Mining: Rev in 1Q Expected to Be Positively Impacted by Unaudited Provisional Pricing Adjustments on Prior-Period Concentrate Sales of Approximately $22M on Pre-Tax Basis >LUN.T

16 apr 2026, 22:06 UTC

Utili

Lundin Mining: Adjustments Primarily Include Upward Adjustments in Relation to Prior-Period Metal Sales >LUN.T

16 apr 2026, 20:50 UTC

Discorsi di Mercato

Utili

Tech, Media & Telecom Roundup: Market Talk

16 apr 2026, 20:50 UTC

Discorsi di Mercato

Financial Services Roundup: Market Talk

16 apr 2026, 20:50 UTC

Discorsi di Mercato

Principali Notizie su Eventi

Basic Materials Roundup: Market Talk

16 apr 2026, 20:50 UTC

Discorsi di Mercato

Utili

Health Care Roundup: Market Talk

16 apr 2026, 20:49 UTC

Utili

SpaceX Is Ready to Go Public. The Stock Market Is Its Rocket. -- Barrons.com

16 apr 2026, 20:43 UTC

Utili

Update: Netflix Stock Falls on Weak Guidance. Founder Reed Hastings Is Leaving the Board. -- Barrons.com

16 apr 2026, 20:40 UTC

Discorsi di Mercato

Utili

Global Equities Roundup: Market Talk

16 apr 2026, 20:40 UTC

Discorsi di Mercato

Utili

Netflix Says Engagement Quality Hits New High -- Market Talk

16 apr 2026, 20:30 UTC

Azioni calde

Stocks to Watch: TSMC, Abbott Laboratories, Nvidia, Netflix -- WSJ

16 apr 2026, 20:25 UTC

Utili

Netflix Stock Falls on Weak Guidance. Founder Reed Hastings Is Leaving the Board. -- Barrons.com

16 apr 2026, 20:23 UTC

Utili

These Stocks Are Today's Movers: AMD, Intel, TSMC, Abbott, Hims, Corning, Schwab, Polaris, and More -- Barrons.com

16 apr 2026, 20:19 UTC

Utili

Netflix Guidance Disappoints. The Stock Is Down. -- Barrons.com

16 apr 2026, 20:17 UTC

Utili

Alcoa: Alumina Costs in the Aluminum Segment Are Expected to Be Favorable by Approximately $20M Sequentially >AA

16 apr 2026, 20:17 UTC

Utili

Alcoa: Based on Higher LME and Midwest Premium Pricing and Expected Higher Shipments, Section 232 Tariff Costs on U.S. Imports of Aluminum From Canada Expected to Increase $35M Sequentially >AA

16 apr 2026, 20:16 UTC

Utili

Alcoa: Expects 2026 Total Aluminum Segment Production and Shipments Ranging Between 2.4M and 2.6M Metric Tons, and Between 2.6M and 2.8M Metric Tons, Respectively >AA

16 apr 2026, 20:16 UTC

Utili

Alcoa: Expects 2026 Total Aluminum Segment Production and Shipments to Remain Unchanged From Its Prior Projection >AA

16 apr 2026, 20:16 UTC

Utili

Alcoa: Expects 2026 Total Alumina Segment Production and Shipments Ranging Between 9.7M to 9.9M Metric Tons, and Between 11.8M and 12.0M Metric Tons, Respectively >AA

16 apr 2026, 20:16 UTC

Utili

Alcoa: Expects 2026 Total Alumina Segment Production and Shipments to Remain Unchanged From Prior Projection >AA

Confronto tra pari

Modifica del prezzo

Crinetics Pharmaceuticals Inc Previsione

Obiettivo di Prezzo

By TipRanks

118.03% in crescita

Previsioni per 12 mesi

Media 86.71 USD 118.03%

Alto 97 USD

Basso 67 USD

Basato su 8 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Crinetics Pharmaceuticals Inc - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Fortemente da comprare

8 ratings

Acquista

Mantieni

Vendi

Basato sugli analisti di 8 che hanno fornito valutazioni azionarie a Crinetics Pharmaceuticals Inc - Dist negli ultimi 3 mesi.

Punteggio Tecnico

By Trading Central

30.39 / 33.46Supporto e resistenza

Recent bullish events outweigh bearish events.

Recent bearish events outweigh bullish events.

The bullish and bearish events are balanced.

Sentiment

By Acuity

332 / 348 Classifica in Settore sanitario

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

Chi Siamo Crinetics Pharmaceuticals Inc

Crinetics Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company's lead product candidate is paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist, which is in Phase 3 trial for the treatment of acromegaly; and Phase 2 trial for treating carcinoid syndrome associated with neuroendocrine tumors. It is also developing CRN04894, an investigational oral nonpeptide product candidate to antagonize the adrenocorticotrophic hormone (ACTH) receptor that has completed a Phase 1 study for the treatment of diseases caused by excess ACTH, including congenital adrenal hyperplasia and Cushing's disease. In addition, the company is developing antagonists of the parathyroid hormone (PTH) receptor for the treatment of primary hyperparathyroidism and humoral hypercalcemia of malignancy, and other diseases of excess PTH; identified investigational orally available somatostatin receptor type 3 targeted nonpeptide agonists for the treatment of autosomal dominant polycystic kidney disease; and developing thyroid-stimulating hormone receptor antagonists for the treatment of graves' disease and thyroid eye disease, as well as Oral GLP-1 and GIP nonpeptides for the treatment of diabetes and obesity. Crinetics Pharmaceuticals, Inc. was incorporated in 2008 and is headquartered in San Diego, California.